第十一批国家药品集采开标，这次有何不同

Core Viewpoint - The eleventh round of national drug procurement has seen increased competition and a significant reduction in the price gap for selected drugs, with a focus on maintaining quality and ensuring that drug prices benefit more patients [2][6][7]. Group 1: Procurement Results - A total of 55 drugs were included in the latest procurement, with 445 companies participating and 272 companies winning selection for 453 products [2]. - The competition level was reported to be much higher than in previous rounds, with the aim of achieving stable clinical outcomes and quality assurance [2][6]. - The selected drugs cover various therapeutic areas, including anti-infection, anti-allergy, anti-tumor, and others, with expected availability starting February 2026 [2]. Group 2: Pricing Dynamics - The average profit margin for generic drugs is reportedly returning to below 10% [1][9]. - The price gap for selected drugs has significantly narrowed compared to previous rounds, with new rules implemented to prevent below-cost bidding [6][7]. - The introduction of a reference price mechanism based on anchor prices aims to ensure that companies can recover costs while offering lower prices [6][7]. Group 3: Participation of Foreign Companies - There is an increasing interest from foreign generic drug companies in participating in China's procurement, with three Indian companies selected this time, compared to none last year [4][3]. Group 4: Changes in Hospital Procurement Authority - Hospitals now have greater autonomy in selecting drugs, allowing them to report demand based on their usage habits and prioritize specific brands [11][12]. - The new rules allow for multiple selected suppliers for each region, enhancing the diversity of available drugs and aligning better with hospital needs [12][13]. - A balance mechanism has been established to prevent monopolies, ensuring that no single company can dominate the procurement volume [12].